Variant:
rs4149015 at chr12:21283322 in SLCO1B1 (VIP)

Alleles (on + chromosomal strand)
G > A
Alternate Names:
SLCO1B1:11187G>A, SLCO1B1:G-11187A, g.14043446G>A, g.4195G>A

Clinical Annotations

To see the clinical annotation for this variant please register or sign in.

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 3 annotations for this variant. Register or sign in to see them.

VIP Variant in SLCO1B1

This is a promoter variant, termed G-11187A. Estimated allelic frequency is G-11187=0.93 and A-11187=0.07 in a Caucasian population (n=41). Carriers of A-11187 exhibited elevated pravastatin plasma AUC and increased pravastatin half-life compared to non-carriers. This was accompanied by reduced hepatocellular pravastatin-induced inhibition of cholesterol synthesis, suggesting lower hepatocellular pravastatin concentrations. Elevated plasma AUC has also been reported in G-11187A carriers exposed to fexofenadine but not repaglinide. This variant is found in conjunction with N130D and V174A.

Key Publications:
Drugs / Other Molecules

Appendix

3. SLC01B1:G-11187A

Genomic Variant & GenBank ID: 14,042,296 G>A on NT_009714
mRNA Variant & GenBank ID: Not Relevant
Protein Variant & GenBank ID: Not Relevant
GoldenPath Position: Chr12:21,174,589 (hg18)

Connected Drugs

Connected Drug Classes

Evidence Drug Class
VIP Annotation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Arsenic compounds

Connected Diseases

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kidney Transplantation

Publications related to rs4149015 at chr12:21283322: 5

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010. Michelon Hugues, et al. [Article:21142914@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). British journal of clinical pharmacology. 2005. Niemi Mikko, et al. [Article:15842561@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical pharmacology and therapeutics. 2005. Niemi Mikko, et al. [Article:15961978@PubMed]
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and genomics. 2005. Niemi Mikko, et al. [Article:15864131@PubMed]
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004. Niemi Mikko, et al. [Article:15226675@PubMed]

Cross-References

UCSC Golden Path:
chr12:21283322
dbSNP:
rs4149015
JSNP:
ssj0003132

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.